APPROPRIATE USE CHECKLIST:
BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS FOR OPIOID DEPENDENCE

This checklist is a useful reminder of the safe use conditions and monitoring requirements for prescribing buprenorphine-containing transmucosal products for opioid dependence.

Requirements to address during each patient’s appointment include:
- understanding and reinforcement of safe use conditions
- the importance of psychosocial counseling
- screening and monitoring patients to determine progress towards treatment goals

If a patient continues to abuse various drugs or is unresponsive to treatment, including psychosocial intervention, it is important that you assess the need to refer the patient to a specialist and/or a more intensive behavioral treatment environment.

Additional resource: Physician Clinical Support System: http://pcssb.org/

This checklist may be used during the induction period and filed in patient’s medical record to document safe use conditions. Once a maintenance dose has been established, use the maintenance checklist.

<table>
<thead>
<tr>
<th>MEASUREMENT TO ENSURE APPROPRIATE USE</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td></td>
</tr>
<tr>
<td><strong>INDUCTION</strong></td>
<td></td>
</tr>
<tr>
<td>Verified patient meets diagnostic criteria for opioid dependence</td>
<td></td>
</tr>
<tr>
<td>Discussed risks described in professional labeling and Medication Guide with patient</td>
<td></td>
</tr>
<tr>
<td>Explained or reviewed conditions of safe storage of medication</td>
<td></td>
</tr>
<tr>
<td>Provided induction doses under appropriate supervision</td>
<td></td>
</tr>
<tr>
<td>Prescribed limited amount of medication at first visit</td>
<td></td>
</tr>
</tbody>
</table>
| Scheduled next visit at interval commensurate with patient stability  
  • Weekly, or more frequent visits recommended for the first month |       |
### APPROPRIATE USE CHECKLIST:
BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS FOR OPIOID DEPENDENCE

This checklist may be used for visits following the induction period and filed in patient's medical record to document safe use conditions.

<table>
<thead>
<tr>
<th>MEASUREMENT TO ENSURE APPROPRIATE USE</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td></td>
</tr>
<tr>
<td>Visit#</td>
<td></td>
</tr>
<tr>
<td><strong>MAINTENANCE</strong></td>
<td></td>
</tr>
<tr>
<td>Assessed and encouraged patient to take medication as prescribed</td>
<td></td>
</tr>
<tr>
<td>• Consider pill/tim count/dose reconciliation</td>
<td></td>
</tr>
<tr>
<td>Assessed appropriateness of dosage</td>
<td></td>
</tr>
<tr>
<td>• Buprenorphine combined with naloxone is recommended for maintenance</td>
<td></td>
</tr>
<tr>
<td>• Generic formulations of Suboxone®: doses ranging from 12 mg to 16 mg of buprenorphine are recommended for maintenance</td>
<td></td>
</tr>
<tr>
<td>• Zubsolv®: a target dose of 11.4 mg buprenorphine is recommended for maintenance</td>
<td></td>
</tr>
<tr>
<td>• Bunavail™: a target dose of 8.4 mg of buprenorphine is recommended for maintenance</td>
<td></td>
</tr>
<tr>
<td>• Doses higher than this should be an exception</td>
<td></td>
</tr>
<tr>
<td>• The need for higher dose should be carefully evaluated</td>
<td></td>
</tr>
<tr>
<td>Conduct urine drug screens as appropriate to assess use of illicit substances</td>
<td></td>
</tr>
<tr>
<td>Assessed participation in professional counseling and support services</td>
<td></td>
</tr>
<tr>
<td>Assessed whether benefits of treatment with buprenorphine-containing products outweigh risks associated with buprenorphine-containing products</td>
<td></td>
</tr>
<tr>
<td>Assessed whether patient is making adequate progress toward treatment goals</td>
<td></td>
</tr>
<tr>
<td>• Considered results of urine drug screens as part of the evidence of the patient complying with the treatment program</td>
<td></td>
</tr>
<tr>
<td>• Consider referral to more intensive forms of treatment for patients not making progress</td>
<td></td>
</tr>
<tr>
<td>Scheduled next visit at interval commensurate with patient stability</td>
<td></td>
</tr>
<tr>
<td>• Weekly, or more frequent visits are recommended for the first month</td>
<td></td>
</tr>
</tbody>
</table>